859538-91-3

Upstream product

• 914221-71-9 2-ethyl-5-(4-methoxyphenyl)-2H-tetrazole 
• 874-90-8 4-methoxybenzonitrile 
• 6926-51-8 5-(4-methoxyphenyl)-2H-tetrazole 
• 6926-51-8 5-(4-methoxyphenyl)-1H-tetrazole 

Downstream Products

• 1026903-49-0 toluene-4-sulfonic acid 5-[4-(2-ethyl-2H-tetrazol-5-yl)-phenoxy]-3-methyl-pentyl ester 
• 1262107-99-2 2-ethyl-5-{4-[(3-(4-nitrophenyl)-5-isoxazolyl)methoxy]phenyl}-2H-tetrazole 
• 1262107-95-8 2-ethyl-5-{4-[(3-(3-nitrophenyl)-5-isoxazolyl)methoxy]phenyl}-2H-tetrazole 
• 897026-57-2 (R/S)-3-(5-benzyloxy-3-chloro-2-methoxyphenyl)-5-(3-(4-(2-ethyltetrazol-5-yl)phenyloxy)propyl)-Δ²-isoxazoline 

Relevant academic research and scientific papers

SSAO INHIBITOR

The present invention provides an SSAO inhibitor and an application thereof in preparing a drug for treating a disease related to SSAO. In particular, the present invention provides a compound shown in formula (IV) and a pharmaceutically acceptable salt thereof.

ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE

Disclosed is a novel anti-enterovirus 71 (EV71) 1,2,5-thiadiazolidine-1,1-dioxide derivative or a pharmaceutically acceptable salt thereof; and specifically, a compound represented by formula (II) or a pharmaceutically acceptable salt thereof.

Design, synthesis, and antipicornavirus activity of 1-[5-(4-arylphenoxy) alkyl]-3-pyridin-4-ylimidazolidin-2-one derivatives

A series of pyridylimidazolidinone derivatives was synthesized and tested in vitro against enterovirus 71 (EV71). On the basis of compound 33 (DBPR103), introduction of a methyl group at the 2- or 3-position of the linker between the imidazolidinone and the biphenyl resulted in markedly improved antiviral activity toward EV71 with IC50 values of 5.0 nM (24b) and 9.3 nM (14a), respectively. Increasing the branched chain to propyl resulted in a progressive decrease in activity, while inserting different heteroatoms entirely rendered the compound only weakly active. The introduction of a bulky group (cyclohexyl, phenyl, or benzyl) led to loss of activity against EV71. The 4-chlorophenyl moiety in 14a was replaced with bioisosteric groups such as oxadiazole (28a-d) or tetrazole (32a,b), dramatically improving anti-EV71 activity and selectivity indices. Compounds 14a, 24b, 28b, 28d, and 32a exhibited a strong activity against lethal EV71, and no apparent cellular toxicity was observed. Three of the more potent imidazolidinone compounds, 14a, 28b, and 32b, were subjected to a large group of picornaviruses to determine their spectrum of antiviral activity.